OCI, located in Barcelona downtown, is a new, young, and dynamic spin-off company invested by Invivo Ventures, CDTI-Innvierte (Ministerio de Industria) and Fundación Internacional Josep Carreras. OCI will focus on the pre-clinical and clinical development of cancer cellular immunotherapy. We are seeking a scientist to lead/conduct projects on cancer immunotherapy. He/she will design and execute in vitro and in vivo cellular, molecular, and immunological assays.
Entidad Financiadora: OneChain Immunotherapeutics